Weekly injections of the GLP-1 semaglutide reduce alcohol consumption in patients with obesity seeking treatment for alcohol ...
Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid ...
Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials ...
In a placebo-controlled randomized trial, adults with obesity and alcohol use disorder had a greater drop in heavy drinking ...
National Institutes of Health (NIH) released the following: A team of National Institutes of Health (NIH) scientists and ...
Once-weekly semaglutide was tied to a reduction in heavy drinking days among adults with obesity and alcohol use disorder, ...
Compared with placebo, semaglutide achieved larger reductions in heavy-drinking days (−41.1 vs −26.4 percentage points) and ...
Everyday Health on MSN
Could Ozempic and Other GLP-1 Drugs Treat Alcohol Use Disorder?
Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol ...
A trial of 108 adults with obesity seeking treatment for alcohol use finds a once-weekly semaglutide injection reduced heavy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results